Since the discovery of epidermal growth factor receptor (EGFR) mutations in lung cancer patients, the development of EGFR tyrosine kinase inhibitors (EGFR-TKIs) has increased the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.